US4607039A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Quinoline derivatives which are 5-hydroxytryptamine antagonists
Assignee: Imperial Chemical Industries Ltd
•
Filing: 1983-04-25
•
Granted: 1986-08-19
•
Expires: 2003-04-25
Abstract
Abstract Compounds of the formula: <IMAGE> wherein A stands for the radical -(CH2)2- which may optionally be substituted by one or two (1-2C)alkyl radicals; Q stands for an oxygen or sulphur atom; R DEG stands for a (1-4C)alkyl, (1-4C)alkoxy or cyclopropyl radical; R1 stands for a defined (3-4C)alkyl radical, a phenyl radical which may optionally bear a defined substituent, or a defined heteroaryl radical of 5 or 6 ring atoms; and R2 and R3 stand for hydrogen or a (1-2C)alkyl radical; and pharmaceutically-acceptable acid-addition salts thereof. Processes for the manufacture of said compounds. Pharmaceutical compositions comprising one of said compounds and a pharmaceutical diluent or carrier. The compounds are 5-hydroxytryptamine antagonists.
Inventors
- 👤 David J. Le Count
- 👤 Robert J. Pearce
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:00
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/20; C07D215/22; C07D215/227; C07D215/18; C07D215/36; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/24; C07D409/00; C07D409/02; C07D409/04
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
108 words
A compound of the formula: ##STR9## wherein: A stands for --(CH 2 ) 2 --, or --(CH 2 ) 2 --which is substituted by not more than two (1-2C) alkyls; Q stands for a sulphur atom; R° stands for (1-4C)alkyl, (1-4C)alkoxy or cyclo-propyl; R 1 stands for a radical selected from the group consisting of n-, iso- or s-(3-4C)alkyl, cyclo-propyl, phenyl, halogenophenyl, (1-2C)alkyl-phenyl, (1-2C)alkoxy-phenyl or (1-2C)perfluoroalkyl-phenyl, heteroaryl of 5 ring atoms having a single hetero-atom selected from oxygen, sulphur and nitrogen atoms and heteroaryl of 6 ring atoms having one nitrogen atom; and R 2 and R 3 each stand for methyl; or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 2
Dependent Claim
108 words
A compound of the formula: ##STR9## wherein: A stands for --(CH 2 ) 2 --, or --(CH 2 ) 2 --which is substituted by not more than two (1-2C) alkyls; Q stands for a sulphur atom; R° stands for (1-4C)alkyl, (1-4C)alkoxy or cyclo-propyl; R 1 stands for a radical selected from the group consisting of n-, iso- or s-(3-4C)alkyl, cyclo-propyl, phenyl, halogenophenyl, (1-2C)alkyl-phenyl, (1-2C)alkoxy-phenyl or (1-2C)perfluoroalkyl-phenyl, heteroaryl of 5 ring atoms having a single hetero-atom selected from oxygen, sulphur and nitrogen atoms and heteroaryl of 6 ring atoms having one nitrogen atom; and R 2 and R 3 each stand for methyl; or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 3
Dependent Claim
23 words
A compound according to claim 1 wherein R° is a radical selected from the group consisting of methyl, n-butyl, methoxy and ethoxy radicals.
Claim 4
Dependent Claim
31 words
A compound according to claim 1 wherein R 1 is a radical selected from the group consisting of n-propyl, isopropyl, n-butyl, cyclo-propyl, phenyl, fluorophenyl, chlorophenyl, bromophenyl, methylphenyl, methoxyphenyl and trifluoromethylphenyl radicals.
Claim 5
Dependent Claim
24 words
A compound according to claim 1 wherein A represents a radical selected from the group consisting of 1,2-ethylene, 1,2-propylene, 2,3-propylene and 1,1-dimethyl-1,2 -ethylene radicals.
Claim 6
Dependent Claim
55 words
A pharmaceutical composition for use as a 5-hydroxytryptamine antagonist, comprising an effective amount of a compound of the formula I, wherein A, Q, R 0 , R 1 , R 2 and R 3 have the meanings stated in claim 1, or a pharmaceutically-acceptable acid-addition salt thereof, and an inert pharmaceutically- acceptable diluent or carrier.
Claim 7
Dependent Claim
16 words
A compound according to claim 1 wherein R 1 is a furyl, thienyl or pyridyl radical.
Claim 8
Dependent Claim
31 words
In a method of treatment which requires the use of a 5-hydroxytryptamine antagonist, the improvement which comprises using, as the antagonist, an effective amount of a compound according to claim 1.
References Cited (Backward Citations)
US16394A
Cited
DE430960C
Cited
US1572768A
Cited
GB349761A
Cited
US1860286A
Cited
US4035374A
Cited
US4260764A
Cited
US4343805A
Cited
US4235909A
Cited
US4426387A
Cited
US4435405A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-08-18 | 1990-02-17 | 1990-08-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-08-18 | 1994-02-17 | 1994-08-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-08-18 | 1998-02-17 | 1998-08-19 | $7700.00 | Window Closed / Lapsed |